- Home
- RPD vs MPLT Comparison
RPD vs MPLT Comparison
Compare RPD & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPD | MPLT |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 780.5M | 811.3M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | RPD | MPLT |
|---|---|---|
| Price | $6.23 | $17.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 21 | 4 |
| Target Price | $16.15 | ★ $31.00 |
| AVG Volume (30 Days) | ★ 1.9M | 157.4K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $685,083,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.93 | N/A |
| P/E Ratio | $17.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.92 | $12.24 |
| 52 Week High | $30.95 | $21.55 |
Technical Indicators
Market Signals| Indicator | RPD | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 15.03 | 55.16 |
| Support Level | N/A | $16.06 |
| Resistance Level | $19.70 | $20.09 |
| Average True Range (ATR) | 0.58 | 1.26 |
| MACD | -0.16 | 0.11 |
| Stochastic Oscillator | 5.33 | 57.69 |
Price Performance
Historical ComparisonAbout RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About MPLT MapLight Therapeutics Inc.
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.